Nordazepam is a long-acting benzodiazepine that is primarily used for its anxiolytic, sedative, muscle relaxant, and anticonvulsant properties. It is also an important active metabolite of several benzodiazepines, including diazepam, chlordiazepoxide, clorazepate, and prazepam, contributing significantly to their prolonged therapeutic effects. Nordazepam was first synthesized during the development of benzodiazepines in the early 1960s by researchers at Hoffmann–La Roche, following the discovery of chlordiazepoxide and diazepam. It was later introduced as a therapeutic agent in several countries under various brand names for the treatment of anxiety disorders and related conditions. Although its direct clinical use has declined due to the availability of newer benzodiazepines with improved pharmacokinetic profiles, nordazepam remains important in clinical pharmacology, forensic toxicology, and pharmaceutical research because of its role as a major metabolite and its long elimination half-life.
